Beese Fulmer Investment Management Inc. Has $3.76 Million Position in Bristol-Myers Squibb Co (BMY)

Beese Fulmer Investment Management Inc. boosted its holdings in Bristol-Myers Squibb Co (NYSE:BMY) by 1.6% during the 4th quarter, HoldingsChannel.com reports. The fund owned 61,318 shares of the biopharmaceutical company’s stock after acquiring an additional 953 shares during the quarter. Beese Fulmer Investment Management Inc.’s holdings in Bristol-Myers Squibb were worth $3,757,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds have also bought and sold shares of the company. Atlantic Trust LLC acquired a new position in shares of Bristol-Myers Squibb during the 2nd quarter valued at $111,000. Massey Quick Simon & CO. LLC increased its position in shares of Bristol-Myers Squibb by 523.5% during the 3rd quarter. Massey Quick Simon & CO. LLC now owns 1,777 shares of the biopharmaceutical company’s stock valued at $113,000 after purchasing an additional 1,492 shares during the period. Blue Chip Partners Inc. increased its position in shares of Bristol-Myers Squibb by 0.7% during the 2nd quarter. Blue Chip Partners Inc. now owns 2,156 shares of the biopharmaceutical company’s stock valued at $120,000 after purchasing an additional 15 shares during the period. Horan Capital Advisors LLC. acquired a new position in shares of Bristol-Myers Squibb during the 3rd quarter valued at $122,000. Finally, BDO Wealth Advisors LLC acquired a new position in shares of Bristol-Myers Squibb during the 2nd quarter valued at $123,000. Hedge funds and other institutional investors own 69.82% of the company’s stock.

BMY has been the topic of several research analyst reports. Zacks Investment Research cut Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Thursday, November 2nd. Vetr cut Bristol-Myers Squibb from a “hold” rating to a “sell” rating and set a $60.72 price target on the stock. in a research report on Tuesday, January 16th. Citigroup set a $72.00 price target on Bristol-Myers Squibb and gave the company a “buy” rating in a research report on Tuesday, December 5th. Credit Suisse Group set a $62.00 price target on Bristol-Myers Squibb and gave the company a “hold” rating in a research report on Monday, January 22nd. Finally, BMO Capital Markets set a $49.00 price target on Bristol-Myers Squibb and gave the company a “sell” rating in a research report on Monday, December 11th. Three equities research analysts have rated the stock with a sell rating, eight have given a hold rating and eight have issued a buy rating to the company’s stock. Bristol-Myers Squibb currently has an average rating of “Hold” and an average target price of $66.18.

Shares of Bristol-Myers Squibb Co (BMY) opened at $67.95 on Friday. The firm has a market capitalization of $111,210.00, a price-to-earnings ratio of 28.79, a PEG ratio of 2.07 and a beta of 1.08. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.43 and a current ratio of 1.55. Bristol-Myers Squibb Co has a one year low of $51.56 and a one year high of $70.05.

Bristol-Myers Squibb (NYSE:BMY) last issued its earnings results on Monday, February 5th. The biopharmaceutical company reported $0.68 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.67 by $0.01. The business had revenue of $5.45 billion during the quarter, compared to analysts’ expectations of $5.35 billion. Bristol-Myers Squibb had a return on equity of 35.43% and a net margin of 4.85%. Bristol-Myers Squibb’s revenue was up 3.9% compared to the same quarter last year. During the same quarter last year, the firm posted $0.63 earnings per share. research analysts anticipate that Bristol-Myers Squibb Co will post 3.21 earnings per share for the current year.

The firm also recently announced a quarterly dividend, which was paid on Thursday, February 1st. Stockholders of record on Friday, January 5th were given a $0.40 dividend. This represents a $1.60 annualized dividend and a dividend yield of 2.35%. The ex-dividend date was Thursday, January 4th. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. Bristol-Myers Squibb’s dividend payout ratio (DPR) is 67.80%.

In other news, EVP Sandra Leung sold 156,582 shares of the firm’s stock in a transaction on Monday, December 4th. The stock was sold at an average price of $63.37, for a total value of $9,922,601.34. Following the completion of the sale, the executive vice president now owns 584,373 shares of the company’s stock, valued at $37,031,717.01. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Thomas J. Jr. Lynch sold 5,300 shares of the firm’s stock in a transaction on Tuesday, December 12th. The stock was sold at an average price of $63.24, for a total value of $335,172.00. Following the completion of the sale, the executive vice president now directly owns 9,251 shares of the company’s stock, valued at approximately $585,033.24. The disclosure for this sale can be found here. Company insiders own 0.23% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Beese Fulmer Investment Management Inc. Has $3.76 Million Position in Bristol-Myers Squibb Co (BMY)” was originally reported by Week Herald and is owned by of Week Herald. If you are accessing this story on another site, it was illegally stolen and reposted in violation of international copyright legislation. The legal version of this story can be viewed at https://weekherald.com/2018/02/24/beese-fulmer-investment-management-inc-has-3-76-million-position-in-bristol-myers-squibb-co-bmy.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply